Navigation Links
Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease

re results, performance or achievements that may be expressed or implied by such forward-looking statements, including, but not limited to, the following:

The Company is still in the development stage and has not generated any revenues. From inception through March 31, 2007, it incurred net losses and negative cash flows from operating activities of approximately $22.7 million and $17.4 million, respectively. Management believes that the Company will continue to incur net losses and cash flow deficiencies from operating activities for the foreseeable future. Because it may take years to develop, test and obtain regulatory approval for a gene-based therapy product before it can be sold, the Company likely will continue to incur significant losses for the foreseeable future. Accordingly, it may never be profitable and, if it does become profitable, it may be unable to sustain profitability.

In order to obtain the regulatory approvals necessary to commercialize its current or future product candidates, from time to time the Company will need to raise funds through public or private equity offerings, debt financings or additional corporate collaboration and licensing arrangements. Availability of financing depends upon a number of factors beyond the Company's control, including market conditions and interest rates. The Company does not know whether additional financing will be available when needed, or if available, will be on acceptable or favorable terms to it or its stockholders. Management believes that the Company's current resources will enable it to continue as a going concern through at least March 31, 2008.

The Company will need to conduct future clinical trials for treatment of Parkinson's disease using the Company's NLX technology. If the trials prove unsuccessful, future operations and the potential for profitability will be materially adversely affected and the business may not succeed.

There is no assurance as to when, or if, th
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:
(Date:11/25/2009)...ov. 25 American Scientif...y") is pleased to announce that they have opened a...ce in Shanghai, China. ,, ASR has been able to ...ateway for the development and production of curre...ren and adults to be distributed and sold globally...
(Date:11/25/2009)...itzerland, Nov. 25 From November ...ive hearing solutions, presented the second editio...ing on the special needs of the older population. ... aging and audiology from around the world and mor... people with hearing loss for an opportunity to sh...
(Date:11/25/2009)...., Nov. 25 AMPAC Fine Chemicals LL...ion (Nasdaq: APFC ) announced today that it recei...ility Award at the Annual Statewide Environmental ...and Technology Association (CMTA), the Industrial ...ndustry Council of California (CICC) held in San D...
Breaking Medicine Technology:American Scientific Resources Inc. Opens Shanghai Location 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 3Terumo Cardiovascular Systems Initiates U S Clinical Trial for Anaconda 28TM 29 AAA Stent Graft System 4777 1Terumo Cardiovascular Systems Initiates U S Clinical Trial for Anaconda 28TM 29 AAA Stent Graft System 4777 2Technology improves salmon passage at hydropower dams 9343 1Technology improves salmon passage at hydropower dams 9343 2Change to Win Statement on Minimum Wage Increase 52654 1
(Date:11/26/2009)...25 years, the number of Americans living with diab...ion in 2009 to 44.1 million in 2034. Over the same...rising from $113 billion to $336 billion, even wit...chers based at the University of Chicago report in...mber of those with diabetes covered by Medicare wi...
(Date:11/26/2009)...ger thrill when on an emotional rollercoaster, stu...y News) -- Call it the fear factor meets the jubil...ctators -- especially those who root for the winni... a closely contested match and victory was in doub..., Chew on that this Thanksgiving weekend as you,...
(Date:11/26/2009)... Research Triangle Dental (RTDental), a...rolina, today announced the expansion of its servi...entist, Dr. Doug Macmillan. , ...ntal is pleased to announce that Dr. Doug Macmilla...mpleted an additional advanced training seminar. ...
(Date:11/25/2009)...INA, Minn., Nov. 25 Whe...their dentist. But a chiropractor can also give p...poral-Mandibular Joint, which is where your jaw (m...al bone). ,, The most common symptoms associat...cking or popping of the jaw. But many other sympt...
(Date:11/25/2009)...ORONTO and CALGARY, Nov. 25 /PRNewswire/ - Sentine...ic Resonance Imaging (MRI) coils and software and ...tware enabling technologies, have introduced a web...tion software. ,, This innovative interface is ...dical imaging offering in the market. Calgary Scie...
Breaking Medicine News(10 mins):Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3
...ead regions' in the brain that could be responsibl...by Karolina Kluk, a Cambridge University student. ...opment of individualized hearing aids for children...not be used with babies. The new electrophysiologi...
...nal examination of a child, to determine the locat...gn of abuse. // This was discussed in the American...in Seattle recently. Retina is a light sensiti...e. A wide variety of conditions such as falls...
...ecalled from the market as stated by the FDA due t...cans. // So this brand would not be sold in market...ant formula, Mead Johnson Nutritionals of EVANSVIL...company for the recall is public health concern. A...
...s, preventing the spread of the deadly virus H5N1,...he Eastern past of France. // The farm in Versaill...y turkeys, was just 200mts away from the lake wher...nion farm has got the bird-flu infection. Nearly 8...
... against indiscriminate antibiotic use, saying th...e prescribed inappropriately. //This issue figure...microbials annual scientific discussion meeting in...ncrease in drug-resistant infections. Prof Tur...
...e complication following coronary artery bypass gr...enon gas, a new study has found. // The results o...d in Anesthesiology journal. The researchers...lopment of new treatments for diseases associated ...
Other Medicine News:Health News:New Test Offers Hope in Effective Hearing Aid Design for Babies 2Health News:Retinal Hemorrhage: No More a Sure Sign of Child Abuse 2
SureCath™ Set - Sterile Intermitent Catheter Set - Male (700mL)
SureCath™ Set - Sterile Intermitent Catheter Set - Female (700mL)
SJM Seguin Annuloplasty Ring
...new Finnpipette Focus from Thermo Labsystems was d...compromising performance. Advanced features such ... adjustment on microvolumes help to define this as...interchangeable handle plate offers a custom fit f...
Medicine Products: